The Bacillus Calmette-Guérin (BCG) vaccine for tuberculosis may reduce the risk of Alzheimer's disease by remodeling the body's immune responses [1].
This finding suggests a potential new pathway for preventing cognitive decline. By understanding how a vaccine designed for a bacterial infection affects the brain, researchers may unlock new methods to protect neurological health in aging populations.
According to the study, the BCG vaccine influences the immune system in a way that may protect the brain from the progression of Alzheimer's [1]. The research indicates that this remodeling of the immune response helps maintain brain health as people age [1].
While the vaccine is primarily used to prevent tuberculosis, its secondary effects on the immune system appear to have broader implications for neurodegenerative diseases [1]. The study suggests that the vaccine's ability to alter how the immune system functions could be the key to its link with lower Alzheimer's risk [1].
Researchers are exploring how these immune changes specifically interact with the brain to prevent the hallmarks of dementia [1]. This connection highlights the complex relationship between the systemic immune system and the central nervous system, a field of study that continues to evolve as scientists seek preventative measures for Alzheimer's [1].
Further research is required to determine the exact mechanisms of this protection and whether the vaccine could be used as a formal preventative tool for those at high risk of cognitive impairment [1].
“The BCG vaccine for tuberculosis may reduce the risk of Alzheimer's disease.”
This research indicates that the immune system's role in brain health is more flexible than previously understood. If a vaccine for a respiratory infection can modulate the brain's susceptibility to Alzheimer's, it opens the door for 'drug repurposing' where existing vaccines or immunotherapies are used to treat non-communicable neurological diseases.
